Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer, has named Sandra Lueken to the role of Vice President, Head of Quality and Regulatory Affairs.

In this role, she will join Selkirk’s executive leadership team and oversee all Quality Unit and Regulatory Affairs functions at the company. Over the past twenty years, Ms. Lueken has held senior level positions in Quality at StrideBio, KBI Biopharma, AstraZeneca, Medimmune, Baxter Biopharma, and HollisterStier.

“Sandra has a rare combination of skill, experience, humility, and passion for patient care,” said Patrick Haffey, CEO of Selkirk. “We are grateful to have her on our team during such an important time for our company.”

Ms. Lueken joins Selkirk just as the company completes construction of its first manufacturing line. She will now oversee commissioning and operational ramp up activities.

Selkirk was founded in 2018 and provides manufacturing (fill and finish) services for injectable drug products, with an emphasis in biologics.